559 related articles for article (PubMed ID: 33894170)
1. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
Azoulay É; Castro P; Maamar A; Metaxa V; de Moraes AG; Voigt L; Wallet F; Klouche K; Picard M; Moreau AS; Van De Louw A; Seguin A; Mokart D; Chawla S; Leroy J; Böll B; Issa N; Levy B; Hemelaar P; Fernandez S; Munshi L; Bauer P; Schellongowski P; Joannidis M; Moreno-Gonzalez G; Galstian G; Darmon M; Valade S;
Lancet Haematol; 2021 May; 8(5):e355-e364. PubMed ID: 33894170
[TBL] [Abstract][Full Text] [Related]
2. Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study.
Caballero-Bellón M; Alonso-Saladrigues A; Bobillo-Perez S; Faura A; Arqués L; Rivera C; Català A; Dapena JL; Rives S; Jordan I
Front Immunol; 2023; 14():1219289. PubMed ID: 37600775
[TBL] [Abstract][Full Text] [Related]
3. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
4. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
5. Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study.
Gutierrez C; Brown ART; May HP; Beitinjaneh A; Stephens RS; Rajendram P; Nates JL; Pastores SM; Dharshan A; de Moraes AG; Hensley MK; Feng L; Brudno JN; Athale J; Ghosh M; Kochenderfer JN; Arias AS; Lin Y; McEvoy C; Mead E; Westin J; Kostelecky N; Mian A; Herr MM
Crit Care Med; 2022 Jan; 50(1):81-92. PubMed ID: 34259446
[TBL] [Abstract][Full Text] [Related]
6. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell Therapy.
Johnson PC; Neckermann I; Sadrzadeh H; Newcomb R; El-Jawahri AR; Frigault MJ
Transplant Cell Ther; 2024 May; 30(5):490-499. PubMed ID: 38412928
[TBL] [Abstract][Full Text] [Related]
8. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
10. Critical Care Management of Chimeric Antigen Receptor T Cell-related Toxicity. Be Aware and Prepared.
Azoulay E; Shimabukuro-Vornhagen A; Darmon M; von Bergwelt-Baildon M
Am J Respir Crit Care Med; 2019 Jul; 200(1):20-23. PubMed ID: 30676776
[TBL] [Abstract][Full Text] [Related]
11. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities.
Gutierrez C; Brown ART; Herr MM; Kadri SS; Hill B; Rajendram P; Duggal A; Turtle CJ; Patel K; Lin Y; May HP; Gallo de Moraes A; Maus MV; Frigault MJ; Brudno JN; Athale J; Shah NN; Kochenderfer JN; Dharshan A; Beitinjaneh A; Arias AS; McEvoy C; Mead E; Stephens RS; Nates JL; Neelapu SS; Pastores SM
J Crit Care; 2020 Aug; 58():58-64. PubMed ID: 32361219
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
[TBL] [Abstract][Full Text] [Related]
13. Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma.
De Philippis C; Mannina D; Giordano L; Costantini E; Marcheselli S; Mariotti J; Sarina B; Taurino D; Santoro A; Bramanti S
Transplant Cell Ther; 2023 Jul; 29(7):429.e1-429.e6. PubMed ID: 36966874
[TBL] [Abstract][Full Text] [Related]
14. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
15. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
Karschnia P; Jordan JT; Forst DA; Arrillaga-Romany IC; Batchelor TT; Baehring JM; Clement NF; Gonzalez Castro LN; Herlopian A; Maus MV; Schwaiblmair MH; Soumerai JD; Takvorian RW; Hochberg EP; Barnes JA; Abramson JS; Frigault MJ; Dietrich J
Blood; 2019 May; 133(20):2212-2221. PubMed ID: 30808634
[TBL] [Abstract][Full Text] [Related]
16. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.
Park JH; Nath K; Devlin SM; Sauter CS; Palomba ML; Shah G; Dahi P; Lin RJ; Scordo M; Perales MA; Shouval R; Tomas AA; Cathcart E; Mead E; Santomasso B; Holodny A; Brentjens RJ; Riviere I; Sadelain M
Nat Med; 2023 Jul; 29(7):1710-1717. PubMed ID: 37400640
[TBL] [Abstract][Full Text] [Related]
17. EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome.
Hernani R; Aiko M; Victorio R; Benzaquén A; Pérez A; Piñana JL; Hernández-Boluda JC; Amat P; Pastor-Galán I; Remigia MJ; Ferrer-Lores B; Micó M; Carbonell N; Ferreres J; Blasco-Cortés ML; Santonja JM; Dosdá R; Estellés R; Campos S; Martínez-Ciarpaglini C; Ferrández-Izquierdo A; Goterris R; Gómez M; Teruel A; Saus A; Ortiz A; Morello D; Martí E; Carretero C; Calabuig M; Tormo M; Terol MJ; Cases P; Solano C
Clin Neurophysiol; 2024 Jul; 163():132-142. PubMed ID: 38733703
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
19. Filgrastim associations with CAR T-cell therapy.
Gaut D; Tang K; Sim MS; Duong T; Young P; Sasine J
Int J Cancer; 2021 Mar; 148(5):1192-1196. PubMed ID: 33091961
[TBL] [Abstract][Full Text] [Related]
20. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]